Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1970 1
1972 1
1973 2
1974 1
1975 1
1976 2
1977 2
1979 1
1980 1
1982 3
1983 2
1984 1
1985 1
1986 3
1987 5
1988 2
1989 3
1990 3
1991 7
1992 1
1993 2
1994 3
1995 3
1996 3
1997 3
1998 2
1999 3
2000 10
2001 11
2002 9
2003 10
2004 14
2005 8
2006 14
2007 7
2008 10
2009 14
2010 19
2011 14
2012 19
2013 20
2014 25
2015 30
2016 24
2017 14
2018 31
2019 42
2020 39
2021 59
2022 63
2023 69
2024 42

Text availability

Article attribute

Article type

Publication date

Search Results

621 results

Results by year

Filters applied: . Clear all
Page 1
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies.
Zhang X, Zhang H, Lan H, Wu J, Xiao Y. Zhang X, et al. Front Immunol. 2023 Feb 20;14:1101495. doi: 10.3389/fimmu.2023.1101495. eCollection 2023. Front Immunol. 2023. PMID: 36891310 Free PMC article. Review.
Due to antigen escape, the poor persistence of CAR-T cells, and the complicated tumor microenvironment, a significant population of MM patients still experience relapse after anti-BCMA CAR-T cell therapy. Additionally, the high manufacturing costs and time-consuming …
Due to antigen escape, the poor persistence of CAR-T cells, and the complicated tumor microenvironment, a significant population of M …
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling.
Weber EW, Parker KR, Sotillo E, Lynn RC, Anbunathan H, Lattin J, Good Z, Belk JA, Daniel B, Klysz D, Malipatlolla M, Xu P, Bashti M, Heitzeneder S, Labanieh L, Vandris P, Majzner RG, Qi Y, Sandor K, Chen LC, Prabhu S, Gentles AJ, Wandless TJ, Satpathy AT, Chang HY, Mackall CL. Weber EW, et al. Science. 2021 Apr 2;372(6537):eaba1786. doi: 10.1126/science.aba1786. Science. 2021. PMID: 33795428 Free PMC article.
T cell exhaustion limits immune responses against cancer and is a major cause of resistance to chimeric antigen receptor (CAR)-T cell therapeutics. Using murine xenograft models and an in vitro model wherein tonic CAR signaling induces hallmark features of exhaustio …
T cell exhaustion limits immune responses against cancer and is a major cause of resistance to chimeric antigen receptor (CAR)-T cell …
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy.
Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, Patchin M, Xu R, Plesa G, Siegel DL, Brennan A, Nelson AM, Ferthio R, Cosey A, Shea KM, Leskowitz R, Four M, Wilson WV, Miao F, Lancaster E, Carreno BM, Linette GP, Hexner EO, Young RM, Bu D, Mansfield KG, Brogdon JL, June CH, Milone MC, Stadtmauer EA. Garfall AL, et al. Blood Cancer Discov. 2023 Mar 1;4(2):118-133. doi: 10.1158/2643-3230.BCD-22-0074. Blood Cancer Discov. 2023. PMID: 36413381 Free PMC article.
We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) patients responding to third- or later-line therapy (phase A, N = 10) or high-risk patients responding …
We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR T cell …
Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma.
Shi X, Yan L, Shang J, Kang L, Yan Z, Jin S, Zhu M, Chang H, Gong F, Zhou J, Chen G, Pan J, Liu D, Zhu X, Tang F, Liu M, Liu W, Yao F, Yu L, Wu D, Fu C. Shi X, et al. Am J Hematol. 2022 May;97(5):537-547. doi: 10.1002/ajh.26486. Epub 2022 Feb 9. Am J Hematol. 2022. PMID: 35114022 Free article. Clinical Trial.
Few prospective studies have examined posttransplant chimeric antigen receptor (CAR) T cell infusion as candidates for front-line consolidation therapy for high-risk multiple myeloma (MM) patients. This single-arm exploratory clinical trial is the first to evaluate the saf …
Few prospective studies have examined posttransplant chimeric antigen receptor (CAR) T cell infusion as candidates for front-line con …
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure.
Wachsmann TLA, Wouters AK, Remst DFG, Hagedoorn RS, Meeuwsen MH, van Diest E, Leusen J, Kuball J, Falkenburg JHF, Heemskerk MHM. Wachsmann TLA, et al. Oncoimmunology. 2022 Feb 1;11(1):2033528. doi: 10.1080/2162402X.2022.2033528. eCollection 2022. Oncoimmunology. 2022. PMID: 35127255 Free PMC article.
As an alternative to CAR T cells, T cells can be engineered to express a tumor-targeting T cell receptor (TCR). ...In contrast, eTCR T cells expanded better than CAR T cells under high antigenic pressure, with lower expression of coinhibitory molecules and mainte …
As an alternative to CAR T cells, T cells can be engineered to express a tumor-targeting T cell receptor (TCR). ...In contrast, eTCR …
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor.
Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. Adachi K, et al. Nat Biotechnol. 2018 Apr;36(4):346-351. doi: 10.1038/nbt.4086. Epub 2018 Mar 5. Nat Biotechnol. 2018. PMID: 29505028
Infiltration, accumulation, and survival of chimeric antigen receptor T (CAR-T) cells in solid tumors is crucial for tumor clearance. We engineered CAR-T cells to express interleukin (IL)-7 and CCL19 (7 19 CAR-T cells), as these factors are essential for the …
Infiltration, accumulation, and survival of chimeric antigen receptor T (CAR-T) cells in solid tumors is crucial for tumor clearance. …
IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19.
Kishimoto T, Kang S. Kishimoto T, et al. Annu Rev Immunol. 2022 Apr 26;40:323-348. doi: 10.1146/annurev-immunol-101220-023458. Epub 2022 Feb 3. Annu Rev Immunol. 2022. PMID: 35113729 Review.
The diverse biological activity of interleukin-6 (IL-6) contributes to the maintenance of homeostasis. Emergent infection or tissue injury induces rapid production of IL-6 and activates host defense through augmentation of acute-phase proteins and immune responses. ...
The diverse biological activity of interleukin-6 (IL-6) contributes to the maintenance of homeostasis. Emergent infection or tissue i …
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells.
Agarwal S, Aznar MA, Rech AJ, Good CR, Kuramitsu S, Da T, Gohil M, Chen L, Hong SA, Ravikumar P, Rennels AK, Salas-Mckee J, Kong W, Ruella M, Davis MM, Plesa G, Fraietta JA, Porter DL, Young RM, June CH. Agarwal S, et al. Immunity. 2023 Oct 10;56(10):2388-2407.e9. doi: 10.1016/j.immuni.2023.09.001. Epub 2023 Sep 29. Immunity. 2023. PMID: 37776850 Free article.
CRISPR-Cas9-mediated deletion of CTLA4 in preclinical models of leukemia and myeloma improved CAR T cell proliferation and anti-tumor efficacy. Importantly, this effect was specific to CTLA4 and not seen upon deletion of CTLA4 and/or PDCD1 in CAR T cells. Mechanisti …
CRISPR-Cas9-mediated deletion of CTLA4 in preclinical models of leukemia and myeloma improved CAR T cell proliferation and anti-tumor …
Introduction to the Immune System.
McComb S, Thiriot A, Akache B, Krishnan L, Stark F. McComb S, et al. Methods Mol Biol. 2019;2024:1-24. doi: 10.1007/978-1-4939-9597-4_1. Methods Mol Biol. 2019. PMID: 31364040
This introduction to the immune system will explore the cell types and soluble factors involved in immune reactions, as well as their location in the body during development and maintenance. Additionally, a description of the immunological events during an innate and adapt …
This introduction to the immune system will explore the cell types and soluble factors involved in immune reactions, as well as their locati …
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
Jabbour E, Short NJ, Jain N, Haddad FG, Welch MA, Ravandi F, Kantarjian H. Jabbour E, et al. J Hematol Oncol. 2023 Mar 16;16(1):22. doi: 10.1186/s13045-023-01409-5. J Hematol Oncol. 2023. PMID: 36927623 Free PMC article. Review.
Our future strategy is to evaluate the early integration of both immunotherapy agents, inotuzumab and blinatumomab, with low-dose chemotherapy (dose-dense mini-Hyper-CVD-inotuzumab-blinatumomab) into the frontline setting followed by CAR T cells consolidation in high-risk …
Our future strategy is to evaluate the early integration of both immunotherapy agents, inotuzumab and blinatumomab, with low-dose chemothera …
621 results